Traders Buy High Volume of Put Options on Dynavax Technologies (DVAX)
Dynavax Technologies Co. (NASDAQ:DVAX) saw unusually large options trading on Monday. Stock investors acquired 2,440 put options on the company. This is an increase of approximately 1,352% compared to the typical daily volume of 168 put options.
In other Dynavax Technologies news, VP David Louis Johnson sold 3,092 shares of the stock in a transaction on Thursday, January 4th. The stock was sold at an average price of $18.60, for a total transaction of $57,511.20. Following the transaction, the vice president now owns 7,780 shares of the company’s stock, valued at approximately $144,708. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Robert Coffman sold 7,500 shares of the stock in a transaction on Wednesday, December 13th. The stock was sold at an average price of $18.90, for a total value of $141,750.00. The disclosure for this sale can be found here. Corporate insiders own 2.90% of the company’s stock.
A number of large investors have recently bought and sold shares of the stock. Vident Investment Advisory LLC grew its stake in Dynavax Technologies by 3.1% in the third quarter. Vident Investment Advisory LLC now owns 150,258 shares of the biopharmaceutical company’s stock worth $3,231,000 after purchasing an additional 4,553 shares in the last quarter. First Republic Investment Management Inc. acquired a new position in Dynavax Technologies in the third quarter worth about $2,414,000. Crawford Lake Capital Management LLC acquired a new position in Dynavax Technologies in the third quarter worth about $1,481,000. California State Teachers Retirement System grew its stake in Dynavax Technologies by 12.0% in the third quarter. California State Teachers Retirement System now owns 97,417 shares of the biopharmaceutical company’s stock worth $2,094,000 after purchasing an additional 10,412 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. grew its stake in Dynavax Technologies by 29.9% in the third quarter. Schwab Charles Investment Management Inc. now owns 235,310 shares of the biopharmaceutical company’s stock worth $5,060,000 after purchasing an additional 54,149 shares in the last quarter. Institutional investors and hedge funds own 70.54% of the company’s stock.
Shares of Dynavax Technologies (DVAX) opened at $16.85 on Thursday. The firm has a market capitalization of $1,020.00, a PE ratio of -8.60 and a beta of 1.31. Dynavax Technologies has a 52 week low of $3.70 and a 52 week high of $24.45.
Dynavax Technologies (NASDAQ:DVAX) last announced its earnings results on Friday, November 3rd. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.15. The company had revenue of $0.05 million during the quarter, compared to the consensus estimate of $0.28 million. Dynavax Technologies had a negative return on equity of 65.97% and a negative net margin of 1,177.60%. The company’s revenue was down 68.8% on a year-over-year basis. During the same period last year, the firm earned ($0.90) earnings per share. research analysts forecast that Dynavax Technologies will post -1.72 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Traders Buy High Volume of Put Options on Dynavax Technologies (DVAX)” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/11/traders-buy-high-volume-of-put-options-on-dynavax-technologies-dvax.html.
About Dynavax Technologies
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.